GRCE — Grace Therapeutics, Income Statement
0.000.00%
Last trade - 00:00- $44.94m
- $24.94m
- 21
- 55
- 74
- 48
Annual income statement for Grace Therapeutics,, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.196 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.12 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16.6 | 15.6 | 52.2 | 12.9 | 16.7 |
| Operating Profit | -16.4 | -15.6 | -52.2 | -12.9 | -16.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.7 | -10.5 | -52 | -14.7 | -12.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19.7 | -9.82 | -42.4 | -12.9 | -9.57 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.7 | -9.82 | -42.4 | -12.9 | -9.57 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19.7 | -9.82 | -42.4 | -12.9 | -9.57 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.65 | -1.57 | -2.74 | -1.25 | -0.792 |